Abstract
We show that heart rate enabled wearable devices can be used to measure respiratory rate. Respiration modulates the heart rate creating excess power in the heart rate variability at a frequency equal to the respiratory rate, a phenomenon known as respiratory sinus arrhythmia. We isolate this component from the power spectral density of the heart beat interval time series, and show that the respiratory rate thus estimated is in good agreement with a validation dataset acquired from sleep studies (root mean squared error = 0.648 min−1, mean absolute percentage error = 3%). Using the same respiratory rate algorithm, we investigate population level characteristics by computing the respiratory rate from 10,000 individuals over a 14 day period, with equal number of males and females ranging in age from 20 - 69 years. 90% of respiratory rate values for healthy adults fall within the range 11.8 min−1 19.2 min−1 with a mean value of 15.4 min−1. Respiratory rate is shown to increase with nocturnal heart rate. It also varies with BMI, reaching a minimum at 25 kg/m2, and increasing for lower and higher BMI. The respiratory rate decreases slightly with age and is higher in females compared to males for age < 50 years, with no difference between females and males thereafter. The 90% range for the coefficient of variation in a 14 day period for females (males) varies from 2.3%−9.2% (2.3%−9.5%) for ages 20−24 yr, to 2.5%−16.8% (2.7%−21.7%) for ages 65−69 yr. We show that respiratory rate is often elevated in subjects diagnosed with COVID-19. In a 7 day window centered on the date when symptoms present (or the test date for asymptomatic cases), we find that 33% (18%) of symptomatic (asymptomatic) individuals had at least one measurement of respiratory rate 3 min−1 higher than the regular rate.
Competing Interest Statement
All authors are affiliated with Fitbit Inc
Funding Statement
We acknowledge funding from Fitbit Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Solutions IRB and Advarra IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.